Cargando…
Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial
PURPOSE: AIO KRK-0104 investigated first-line therapy of metastatic colorectal cancer (mCRC) with cetuximab, capecitabine and irinotecan versus cetuximab, capecitabine and oxaliplatin. This analysis investigated the impact of primary tumor location on outcome of patients. PATIENTS AND METHODS: Left-...
Autores principales: | von Einem, J. C., Heinemann, V., von Weikersthal, L. Fischer, Vehling-Kaiser, U., Stauch, M., Hass, H. G., Decker, T., Klein, S., Held, S., Jung, A., Kirchner, T., Haas, M., Holch, J., Michl, M., Aubele, P., Boeck, S., Schulz, C., Giessen, C., Stintzing, S., Modest, D. P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4131148/ https://www.ncbi.nlm.nih.gov/pubmed/24816724 http://dx.doi.org/10.1007/s00432-014-1678-3 |
Ejemplares similares
-
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial
por: Stintzing, S, et al.
Publicado: (2011) -
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial
por: Stintzing, S, et al.
Publicado: (2019) -
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial
por: Giessen, Clemens, et al.
Publicado: (2011) -
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104
por: Boeck, S, et al.
Publicado: (2013) -
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306
por: Hofmann, Felix O., et al.
Publicado: (2022)